A recent study published in Current Diabetes Review highlighted the role of triple combination therapy of teneligliptin with metformin and glimepiride in controlling glucose, reducing insulin resistance with a positive effect on hepatic, renal, and lipid profiles without serious adverse drug reactions such as hypoglycemia.
The study investigated the safety and efficacy of combining metformin, teneligliptin, and glimepiride in the treatment of T2DM patients.
The study involved 300 T2DM patients divided into three groups. Group 1 was metformin alone treated (n=100), group 2 was Metformin + Teneligliptin (n=100), and group 3 was Metformin + teneligliptin + glimepiride (n=100). Researchers collected data on PPBS, HbA1c, FBS, fasting insulin, HOMA-IR, C-Peptide, QUICKI-IR, and hepatic, lipid, and renal profiles at the start of the study and after 3, 6, and 12 months. SPSS 21.0 software was used to analyze data.
Results showed that at the end of 12 months, there was a significant reduction in fasting insulin (11.26±2.5 IU), PPBS (9.39±2.14 mg/dl), FBS (7.6±1.41 mg/dl), insulin resistance (3.74±0.7), C-peptide (2.01±2.29 ng/ml), and fasting insulin (11.26±2.5 IU) by HOMA-IR in the triple therapy group. A significant glycemic control was also achieved by the triple therapy group, with a favorable lipid profile compared to the other groups. Even though renal and hepatic profile variations were seen, the values were within the normal range.
• The combination of teneligliptin, metformin, and glimepiride significantly improved HbA1c levels and reduced insulin resistance in T2DM patients.
• The therapy had positive effects on renal, lipid, and hepatic parameters.
• There were no serious adverse effects, like hypoglycemia.
• While results are promising, larger randomized controlled trials (RCTs) should be conducted to confirm the efficacy and safety of this triple-drug regimen.
Manchi RK, Chenchula S, Haritha M. Effectiveness and Safety of Metformin, Teneligliptin, and Glimepiride Combination Therapy in Type 2 Diabetes: A Quasi Experimental Clinical Trial. Curr Diabetes Rev. 2025;21(6):102-111. doi:10.2174/0115733998292943240730115310
There is role of triple combination therapy of teneligliptin with metformin and glimepiride in controlling glucose, reducing insulin resistance with a positive effect on hepatic, renal, and lipid profiles.